Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00derived— vs Q3 2021 Net Income-$6.02M-$6.02MN/M vs Q3 2021 EPS Diluted-$0.37-$0.37N/M vs Q3 2021 Operating Income-$6,057,118N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,974,319N/M ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end